
1. N Engl J Med. 2017 Apr 27;376(17):1615-1626. doi: 10.1056/NEJMoa1610528.

Overexpression of the Cytokine BAFF and Autoimmunity Risk.

Steri M(1), Orrù V(1), Idda ML(1), Pitzalis M(1), Pala M(1), Zara I(1), Sidore
C(1), Faà V(1), Floris M(1), Deiana M(1), Asunis I(1), Porcu E(1), Mulas A(1),
Piras MG(1), Lobina M(1), Lai S(1), Marongiu M(1), Serra V(1), Marongiu M(1),
Sole G(1), Busonero F(1), Maschio A(1), Cusano R(1), Cuccuru G(1), Deidda F(1),
Poddie F(1), Farina G(1), Dei M(1), Virdis F(1), Olla S(1), Satta MA(1), Pani
M(1), Delitala A(1), Cocco E(1), Frau J(1), Coghe G(1), Lorefice L(1), Fenu G(1),
Ferrigno P(1), Ban M(1), Barizzone N(1), Leone M(1), Guerini FR(1), Piga M(1),
Firinu D(1), Kockum I(1), Lima Bomfim I(1), Olsson T(1), Alfredsson L(1), Suarez 
A(1), Carreira PE(1), Castillo-Palma MJ(1), Marcus JH(1), Congia M(1), Angius
A(1), Melis M(1), Gonzalez A(1), Alarcón Riquelme ME(1), da Silva BM(1), Marchini
M(1), Danieli MG(1), Del Giacco S(1), Mathieu A(1), Pani A(1), Montgomery SB(1), 
Rosati G(1), Hillert J(1), Sawcer S(1), D'Alfonso S(1), Todd JA(1), Novembre
J(1), Abecasis GR(1), Whalen MB(1), Marrosu MG(1), Meloni A(1), Sanna S(1),
Gorospe M(1), Schlessinger D(1), Fiorillo E(1), Zoledziewska M(1), Cucca F(1).

Author information: 
(1)From Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle
Ricerche Monserrato (M.S., V.O., M.L.I., M. Pitzalis, M. Pala, C.S., V.F., M.F., 
M. Deiana, I.A., E.P., A. Mulas, M.G.P., M. Lobina, S.L., Mara Marongiu, V.S.,
Michele Marongiu, G.S., F.B., A. Maschio, F.D., M. Dei, F.V., S.O., A.A., M.B.W.,
A. Meloni, S. Sanna, E.F., M.Z., F.C.), Center for Advanced Studies, Research,
and Development in Sardinia, Parco Scientifico e Tecnologico della Sardegna
(I.Z., M.F., R.C., G. Cuccuru), Struttura Complessa Disciplina di Ematologia e
Centro Trapianto Cellule Staminali Emopoietiche Wilma Deplano, Ospedale
Oncologico di Riferimento Regionale Armando Businco (M. Pani), Dipartimento di
Sanità Pubblica, Medicina Clinica e Molecolare, Università di Cagliari (E.C.,
J.F., G. Coghe, L.L., G. Fenu), Azienda Ospedaliera Brotzu, S.C. Neurologia
(P.F., M. Melis), Division of Rheumatology, University and University Hospital of
Cagliari (M. Piga, A. Mathieu), Department of Medical Sciences M. Aresu,
University of Cagliari (D.F., S.D.G., M.G.M.), Azienda Ospedaliera Brotzu, U.S.
Gastroenterologia Pediatrica Ospedale Pediatrico Microcitemico A. Cao (M.C.), and
Nephrology, Dialysis, and Transplantation Unit, Giuseppe Brotzu Hospital (A.P.), 
Cagliari, Dipartimento di Scienze Biomediche, Università degli Studi di Sassari
(M.F., F.P., F.C.), Unit of Neurology, Department of Clinical and Experimental
Medicine, University of Sassari (G. Farina, G.R.), and Servizio Trasfusionale
(M.A.S.) and Clinica Medica (A.D.), Azienda Ospedaliero Universitaria di Sassari,
Sassari, Neurology B, Department of Neurological, Biomedical, and Movement
Sciences, University of Verona, Verona (G. Farina), Department of Health
Sciences, Interdisciplinary Research Center of Autoimmune Diseases, University of
Eastern Piedmont, Novara (N.B., S.D.), SC Neurologia, Dipartimento di Scienze
Mediche, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa
Sollievo della Sofferenza, San Giovanni Rotondo (M. Leone), Don C. Gnocchi
Foundation IRCCS (F.R.G.), and Referral Center for Systemic Autoimmune Diseases
Fondazione IRCCS Cá Granda Ospedale Maggiore Policlinico and University of Milan 
(M. Marchini), Milan, and Dipartimento di Scienze Cliniche e Molecolari,
Università Politecnica delle Marche e Ospedali Riuniti, Ancona (M.G.D.) - all in 
Italy; Laboratory of Genetics and Genomics, National Institute on Aging, National
Institutes of Health, Baltimore (M.L.I., M.G., D.S.); the Department of Clinical 
Neurosciences (M.B., S. Sawcer) and JDRF-Wellcome Trust Diabetes and Inflammation
Laboratory, National Institute for Health Research Cambridge Biomedical Research 
Centre, Cambridge Institute for Medical Research (J.A.T.), University of
Cambridge, Cambridge, United Kingdom; Department of Clinical Neuroscience,
Karolinska Institutet at Karolinska University Hospital Solna (I.K., I.L.B.,
T.O., J.H.), Institute of Environmental Medicine (L.A.) and Institute of
Environmental Medicine, Unit of Immunology and Chronic Disease (M.E.A.R.),
Karolinska Institute, and Center for Occupational and Environmental Medicine,
Stockholm County Council (L.A.), Stockholm; Department of Functional Biology,
University of Oviedo, Oviedo (A.S.), Rheumatology Department, Hospital
Universitario 12 de Octubre, Madrid (P.E.C.), Department of Internal Medicine,
Hospital Universitario Virgen del Rocío, Seville (M.J.C.-P.), Laboratorio de
Investigacion 10 and Rheumatology Unit, Instituto de Investigacion
Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela
(A.G.), and Centro de Genómica e Investigación Oncológica, Pfizer-Universidad de 
Granada-Junta de Andalucía, Granada (M.E.A.R.) - all in Spain; Department of
Human Genetics, University of Chicago, Chicago (J.H.M., J.N.); Centro Hospitalar 
do Porto-Hospital Santo Antonio and Unit for Multidisciplinary Research in
Biomedicine-Unidade Multidisciplinar de Investigação Biomédica, Porto, Portugal
(B.M.S.); Departments of Pathology and Genetics, Stanford University, Stanford,
CA (S.B.M.); and Center for Statistical Genetics, University of Michigan, Ann
Arbor (G.R.A.).

Comment in
    Nat Rev Rheumatol. 2017 Aug;13(8):456-457.

BACKGROUND: Genomewide association studies of autoimmune diseases have mapped
hundreds of susceptibility regions in the genome. However, only for a few
association signals has the causal gene been identified, and for even fewer have 
the causal variant and underlying mechanism been defined. Coincident associations
of DNA variants affecting both the risk of autoimmune disease and quantitative
immune variables provide an informative route to explore disease mechanisms and
drug-targetable pathways.
METHODS: Using case-control samples from Sardinia, Italy, we performed a
genomewide association study in multiple sclerosis followed by TNFSF13B
locus-specific association testing in systemic lupus erythematosus (SLE).
Extensive phenotyping of quantitative immune variables, sequence-based fine
mapping, cross-population and cross-phenotype analyses, and gene-expression
studies were used to identify the causal variant and elucidate its mechanism of
action. Signatures of positive selection were also investigated.
RESULTS: A variant in TNFSF13B, encoding the cytokine and drug target B-cell
activating factor (BAFF), was associated with multiple sclerosis as well as SLE. 
The disease-risk allele was also associated with up-regulated humoral immunity
through increased levels of soluble BAFF, B lymphocytes, and immunoglobulins. The
causal variant was identified: an insertion-deletion variant, GCTGT→A (in which A
is the risk allele), yielded a shorter transcript that escaped microRNA
inhibition and increased production of soluble BAFF, which in turn up-regulated
humoral immunity. Population genetic signatures indicated that this autoimmunity 
variant has been evolutionarily advantageous, most likely by augmenting
resistance to malaria.
CONCLUSIONS: A TNFSF13B variant was associated with multiple sclerosis and SLE,
and its effects were clarified at the population, cellular, and molecular levels.
(Funded by the Italian Foundation for Multiple Sclerosis and others.).

DOI: 10.1056/NEJMoa1610528 
PMCID: PMC5605835
PMID: 28445677  [Indexed for MEDLINE]

